Personalis, Inc.

Personalis, Inc. (PSNL) Market Cap

Personalis, Inc. has a market capitalization of $560.4M.

Financials based on reported quarter end 2025-12-31

Price: $6.31

β–² 0.07 (1.12%)

Market Cap: 560.36M

NASDAQ Β· time unavailable

CEO: Christopher Hall

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 2019-06-20

Website: https://www.personalis.com

Personalis, Inc. (PSNL) - Company Information

Market Cap: 560.36M Β· Sector: Healthcare

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Analyst Sentiment

81%
Strong Buy

Based on 12 ratings

Analyst 1Y Forecast: $10.20

Average target (based on 3 sources)

Consensus Price Target

Low

$10

Median

$11

High

$13

Average

$11

Potential Upside: 78.3%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ PERSONALIS INC (PSNL) β€” Investment Overview

🧩 Business Model Overview

PERSONALIS INC operates a data-driven customer platform that converts client data into actionable, personalized experiences. The value chain typically spans (1) client data ingestion and normalization, (2) proprietary modeling/segmentation that generates personalization outputs, and (3) delivery of those outputs through client-facing workflows (e.g., operational execution, customer/employee touchpoints, or decision support). The model relies on ongoing configuration and integration with each customer’s environment, which creates practical continuity in the customer relationship rather than purely project-based delivery.

From a stickiness perspective, the company’s platform is best understood as an β€œembedded capability” that improves with use: data feedback loops, template/workflow refinement, and operational tuning reduce friction over time for both the customer and the vendor.

πŸ’° Revenue Streams & Monetisation Model

Monetisation generally blends recurring software/platform revenue with implementation and services. The recurring component tends to be tied to ongoing usage (or client seats/instances), enabling a higher proportion of gross margin over time as deployments mature. Implementation and onboarding revenue typically funds initial integration and configuration, after which the account moves into a lower-touch operating cadence.

Margin drivers include: (1) software mix (subscription/usage-based revenue generally carries structurally higher margins than services), (2) onboarding efficiency (repeatable deployment patterns), and (3) retention economics (renewals and expansion are usually less costly to win than net-new logos). The most important driver for profitability is sustained renewal/usage growth while keeping sales and implementation costs disciplined per customer.

🧠 Competitive Advantages & Market Positioning

The key moat is a combination of switching costs and accumulated domain data/learning, supported by integration depth.

  • Switching costs (hard to replicate): Personalization systems become operationally embedded through integrations, workflow dependencies, security controls, and business-rule customization. Replacing a vendor typically requires re-implementing these components and re-establishing performance baselines.
  • Accumulated data and learning (intangible asset): Performance improves as models and rules adapt to how a client’s population and journeys behave. Even if competitors match functionality, replicating the same outcomes across the same operational constraints is non-trivial.
  • Integration and implementation know-how: Competitors can offer similar β€œfeatures,” but practical deployment is where differentiation often persistsβ€”data mapping, identity resolution, governance, and day-to-day tuning.

Net effect: the company is positioned not as a one-time analytics vendor, but as an ongoing personalization capability. That structural customer lock-in typically supports resilience through budget cycles and raises the probability of account expansion over time.

πŸš€ Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular demand for personalization and data-enabled decisioning across industries where customer experience, engagement, and outcomes materially affect retention and revenue.

  • Personalization becoming default expectation: As customers and users expect tailored experiences, organizations shift from static segmentation to continuous personalization.
  • Better economics through optimization: Targeted engagement and smarter decisioning can reduce waste (e.g., inefficient communications) and improve conversion/retention, motivating re-investment.
  • Platformization of workflows: Companies move from point solutions to integrated platforms; once embedded, personalization expands to additional workflows and lines of business.
  • Data infrastructure improvements: Growth in accessible, governable data makes personalization more feasible and measurable, expanding TAM for vendors with deployment expertise.

TAM expansion is likely driven by both (1) increased penetration within existing clients through deeper workflow adoption and (2) new customer acquisition in organizations prioritizing measurable ROI from personalization.

⚠ Risk Factors to Monitor

  • Competitive displacement: Larger incumbents or well-funded entrants can compress differentiation by bundling personalization into broader suites.
  • Technological disruption: Shifts in model architectures, identity resolution approaches, or personalization paradigms can reduce the value of legacy implementations unless the platform evolves.
  • Data governance and privacy constraints: Regulation and evolving consent requirements can limit data availability and increase compliance costs.
  • Customer concentration and budget timing: Enterprise deployments can be lumpy; renewal and expansion depend on customer-level business priorities.
  • Implementation complexity: Higher-than-expected onboarding effort can pressure margins and slow scaling.

πŸ“Š Valuation & Market View

Market valuation for software/data-enabled platforms often emphasizes revenue quality (recurring mix and retention), scalability (gross margin trajectory and operating leverage), and growth durability (evidence of expansion and durable renewal cohorts). As a result, investors frequently anchor on metrics such as EV/Sales or EV/Revenue for earlier-stage profiles and EV/EBITDA for later-stage cash generation, with the weighting dependent on growth and margin confidence.

Key valuation sensitivities typically include: (1) visibility of recurring revenue, (2) net retention/expansion signals, (3) evidence of repeatable onboarding reducing cost per deployment, and (4) durability of differentiation versus suite competitors.

πŸ” Investment Takeaway

PERSONALIS INC’s long-term investment case rests on the structural persistence of personalization workflows once embedded: switching costs, integration depth, and accumulated learning/data-driven performance create a practical moat. If the company maintains disciplined onboarding efficiency and continues translating deployments into recurring, expanding usage, the business model is positioned to compound value over a multi-year horizon despite competitive noise.


⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"PSNL reported revenue of $17.3M, but faced a net loss of $23.8M for the year ending December 31, 2025. The company has shown strong price appreciation with a 1-year gain of 102.6%, indicating significant market interest. Despite this, cash flow remains a concern, with negative operating cash flow of $22.2M and free cash flow of -$22.3M. The balance sheet shows total assets of $334.2M against total liabilities of $72.98M, providing a solid equity position of $261.2M and negative net debt of $92.38M, indicating financial stability despite operational challenges. Overall, while pricing shows favorable market perception, profitability and cash flow metrics suggest that operational improvements are necessary for sustainable growth."

Revenue Growth

Fair

Minimal revenue growth presents concerns despite profitability challenges.

Profitability

Neutral

Net income remains negative, indicating ongoing losses.

Cash Flow Quality

Neutral

Negative cash flow impacts financial stability.

Leverage & Balance Sheet

Good

Strong balance sheet with high equity and negative net debt.

Shareholder Returns

Strong

Strong price appreciation indicates positive market sentiment.

Analyst Sentiment & Valuation

Fair

Consensus price target suggests potential for modest growth.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered a clear growth story on Clinical volumes (6,183 tests in Q4; +329% YoY) and highlighted Medicare coverage wins (breast in Q4; lung shortly before the call) that improve unit economics. However, the Q&A reinforces that the stock’s fundamental inflection is still dependent on reimbursement conversion timing: gross margin was just 11% in Q4 and was diluted by ~1,900 bps from unreimbursed costs; 2026 gross margin is guided at 15%–20% with Q1 as the trough until IO converts (explicitly not assumed in the guide). The analyst pressure focused on execution mechanics (reps/Tempus focus, mix of reimbursed vs unreimbursed, whether early access physicians actually opt in, and cash runway interpretation). Management responded with concrete scaling steps (double reps from ~10 to ~20; Tempus CRC expansion; increasing physician adoption) and provided a stable biopharma demand view (no pushouts/cancellations). Net: strong momentum, but near-term profitability and cash flow hinge on reimbursement timing rather than only volume growth.

AI IconGrowth Catalysts

  • Clinical tests 6,183 in Q4 2025 (+41% sequential; +329% YoY)
  • Full-year 2025 Clinical tests >16,000 (+394% YoY)
  • NeXT Personal Medicare coverage expansion to breast cancer (Q4) and lung cancer (received shortly before call)
  • Real-time variant tracker module (opt-in early access program launched January 2026)

Business Development

  • Tempus partnership expanded in 2025 to include colorectal cancer; also Tempus provides commercial infrastructure
  • Moderna support for INT program (referenced as a potential driver of revenue over out years)
  • Medicare coverage processes: MolDX dossier under review for immunotherapy monitoring in metastatic cancer (IO)
  • Medicare coverage wins referenced as evidence-backed: breast and lung

AI IconFinancial Highlights

  • Q4 2025 revenue: $17.3M (in line with prior; +3% YoY vs $16.8M)
  • Full-year 2025 revenue: $69.6M; described as impacted by planned Natera revenue decline (~$19.5M) and Moderna melanoma trial enrollment conclusion (~$10M decline)
  • Q4 2025 gross margin: 11%; full-year gross margin: 22.7%
  • Unreimbursed costs diluted gross margin by ~1,900 basis points in Q4
  • Full-year biopharma MRD revenue grew nearly 240% YoY
  • Q4 net loss: $23.8M; full-year net loss: $81.3M (flat vs 2024)
  • 2026 guidance gross margin: 15%–20%, with Q1 expected to be the lowest point (before IO coverage converts to revenue)

AI IconCapital Funding

  • Cash & short-term investments: $240M at end of Q4 2025
  • No debt other than small equipment loans
  • 2025 cash use: ~$74M (just under $75M guidance)
  • 2026 expected cash usage: ~ $100M

AI IconStrategy & Ops

  • Intentionally planned margin dilution to invest ahead of reimbursement; margin pressure expected to continue into 2026 until IO converts
  • Clinical scaling ahead of reimbursement: about half of volume noted as Medicare-related, and fee-for-service roughly half of that; many tests are still effectively 'zeros' outside covered indications
  • Commercial expansion plan: add ~10 more reps; ended the year with 10 reps and expects to double to ~20 reps (Tempus-aligned)

AI IconMarket Outlook

  • 2026 total revenue guidance: $78M–$80M
  • 2026 Clinical revenue guidance: $10M–$11M (breast + lung surveillance covered by Medicare)
  • 2026 biopharma MRD revenue guidance: $20M–$21M
  • 2026 population sequencing + enterprise customers: ~ $13M
  • 2026 Clinical test volume guidance: 43,000–45,000 tests (~170% YoY growth)
  • IO coverage: acknowledged as 'in front of us'; not assumed in the prepared volume/revenue guidance (per discussion that the guide did not assume IO yet)

AI IconRisks & Headwinds

  • Unreimbursed testing costs materially compress gross margin (noted at ~1,900 bps dilution in Q4)
  • Margin trough risk in 2026 Q1 until additional reimbursement coverage (IO) begins converting to revenue
  • Biopharma variability risk persists, though management stated they are not seeing pushouts/cancellations now (sector stabilizing vs last year)
  • Operational note: volume mix currently includes many 'zeros' (tests run for indications not yet reimbursed; less than half of tests are attributed to only breast and lung coverage at current stage)
  • Seasonality in Clinical volumes: Q1 and Q3 typically slower; Q2 and Q4 strongest

Sentiment: MIXED

Note: This summary was synthesized by AI from the PSNL Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (PSNL)

Β© 2026 Stock Market Info β€” Personalis, Inc. (PSNL) Financial Profile